Clinical Trials of Respiratory Virus Infections: How to Address Challenges and Prepare for the Future  

作　　者：Jingwen Ai Wenhong Zhang 

机构地区：[1]Department of Infectious Diseases,Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response,National Medical Center for Infectious Diseases,Huashan Hospital,Shanghai Medical College,Fudan University,Shanghai 200040,China [2]Shanghai Sci-Tech InnoCenter for Infection and Immunity,Shanghai 20052,China [3]Institute of Infection and Health,Fudan University,Shanghai 200040,China.

出　　处：《Infectious Diseases & Immunity》2024年第3期101-102,共2页感染性疾病与免疫（英文）

基　　金：supported by National Natural Science Foundation of China(82341033,82161138018);National Key Research and Development Program(2023YFC3043507).

摘　　要：1.Backgrounds Prior to the coronavirus disease 2019(COVID-19)outbreak,the only antiviral treatment widely used in clinical settings was for influenza.However,following the global pandemic,there has been renewed research interest in medications for respiratory viral infections.Clinical trials of antiviral medications often need to consider multiple dimensions because of the significant differences in disease severity among populations.For example,during respiratory viral epidemic seasons,the clinical spectrum of diseases is usually complex,including asymptomatic infections,symptomatic infections(mild to moderate without hospitalization),severe cases(requiring hospitalization),and fatalities.

关 键 词：CLINICAL RESPIRATORY CLINICAL 

分 类 号：R373.1[医药卫生—病原生物学]